![](https://endpts.com/wp-content/uploads/2022/02/UCB-tile-website1-scaled.jpg)
How UCB beat 2 other bidders to land $1.9B buyout of Zogenix and its epilepsy drug
Days before it would nail down the FDA’s approval for its epilepsy drug Fintepla, Zogenix received one of the first inquiries from a pharma company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.